GLP-1 Drugs: Lower Risk of Heart Attack, Stroke & Death – New Study

New research suggests that GLP-1 drugs, initially developed for managing type 2 diabetes and gaining popularity for weight loss, offer sustained protection against major cardiovascular events like heart attack and stroke. An analysis of data from over 90,000 patients participating in large international studies revealed a significantly lower risk of cardiovascular problems among individuals treated with glucagon-like peptide-1 (GLP-1) receptor agonists compared to those receiving a placebo.

The findings, initially reported by Medical Xpress, build upon a growing body of evidence demonstrating the cardiovascular benefits of these medications. While previous studies have indicated a link between GLP-1 drugs and improved heart health, this research highlights the long-term nature of those benefits.

GLP-1 Drugs and Cardiovascular Risk Reduction

The study, conducted by researchers at Anglia Ruskin University (ARU), examined data from multiple large-scale international trials. Participants treated with GLP-1 receptor agonists experienced a notable reduction in major adverse cardiovascular events (MACE), encompassing heart attack, stroke, and cardiovascular death. The specific magnitude of risk reduction varied across studies, but the overall trend consistently pointed towards a protective effect.

GLP-1 receptor agonists work by mimicking the effects of the naturally occurring GLP-1 hormone, which plays a role in regulating blood sugar levels and appetite. These drugs stimulate insulin release, suppress glucagon secretion, and slow gastric emptying, leading to improved glycemic control and weight loss. Increasingly, research suggests these metabolic effects translate into tangible cardiovascular benefits.

Confirmation from Multiple Studies

The ARU analysis corroborates findings from several other recent investigations. A study published in Nature Medicine in November 2025, conducted by researchers at Mass General Brigham, compared the cardioprotective effects of tirzepatide (Mounjaro) and semaglutide (Ozempic). The researchers found that both medications reduced the risk of heart attack, stroke, and death from any cause. The study utilized national claims databases to compare outcomes among nearly one million adults with type 2 diabetes.

That research indicated that the benefits of tirzepatide and semaglutide were comparable, with only minor differences observed. According to Nils Krüger, MD, a research fellow at Mass General Brigham, “Randomized controlled trials are often considered the reference standard in the medical evidence generation process. However, not all questions can be answered using this time- and resource-intensive method. Data generated in clinical practice and used secondarily for research allow us to address a wide range of clinically relevant questions time- and resource-effectively—when applied correctly.”

A separate study from the Technical University of Munich (TUM) and Harvard Medical School, also published in November 2025, similarly demonstrated the heart-protective effects of semaglutide and tirzepatide. Analyzing real-world insurance data, the researchers reported up to an 18% reduction in major cardiovascular events among patients taking these medications compared to those taking dulaglutide, an older GLP-1 drug.

The Risks of Discontinuation

However, recent research also highlights the importance of continuous treatment with GLP-1 drugs to maintain these cardiovascular benefits. A study conducted by researchers at Washington University School of Medicine in St. Louis, published in BMJ Medicine on March 18, 2026, followed over 333,000 U.S. Veterans with type 2 diabetes for three years. The study found that stopping or interrupting GLP-1 treatment for as little as six months was linked to a significant increase in the risk of major cardiovascular events.

The risk increased with the duration of treatment interruption, reaching up to a 22% increase in the risk of heart attack, stroke, and death after two years off GLP-1s. Ziyad Al-Aly, MD, a clinical epidemiologist at WashU Medicine, emphasized the importance of continuous treatment, stating, “There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop. Many quit after a few months because of cost, side effects or shortages. When they stop, it’s not just weight that comes back; they experience a resurgence in inflammation, blood pressure, and cholesterol.”

The researchers noted that the consequences of stopping GLP-1 drugs extend beyond weight regain, impacting cardiovascular health and underscoring the need for sustained treatment to realize lasting protection.

These findings reinforce the growing understanding of GLP-1 drugs as more than just weight-loss medications, positioning them as potentially valuable tools in the prevention and management of cardiovascular disease, particularly among individuals with type 2 diabetes. Further research is ongoing to fully elucidate the mechanisms underlying these benefits and to determine the optimal duration and strategies for GLP-1 therapy.